{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dieci MV"],"funding":["Agenzia Italiana del Farmaco, Ministero della Salute"],"pagination":["207"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6868696"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(1)"],"pubmed_abstract":["<h4>Background</h4>The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic stage in HER2-positive breast cancer patients enrolled in the ShortHER trial.<h4>Methods</h4>The ShortHER trial randomized 1253 HER2-positive patients to 9 weeks or 1 year of adjuvant trastuzumab combined with chemotherapy. Patients were classified according to the anatomic and the prognostic stage. Distant disease-free survival (DDFS) was calculated from randomization to distant relapse or death.<h4>Results</h4>A total of 1244 patients were included. Compared to anatomic stage, the prognostic stage downstaged 41.6% (n = 517) of patients to a more favorable stage category. Five"],"journal":["BMC medicine"],"pubmed_title":["Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial."],"pmcid":["PMC6868696"],"funding_grant_id":["FARM62MC97"],"pubmed_authors":["Sarti S","Zamagni C","Foschini MP","Moretti G","Gambaro AR","Frassoldati A","Aieta M","Guarneri V","Gebbia V","Romito S","Ferro A","Bazan V","Vicini R","Brandes AA","Musolino A","Amaducci L","Giotta F","D'Amico R","Danese S","Cagossi K","Soto Parra H","Rimanti A","Bisagni G","Cavanna L","Griguolo G","Conte PF","Donadio M","Garrone O","Piacentini F","Dieci MV","Balduzzi S","Beano A"],"additional_accession":[]},"is_claimable":false,"name":"Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.","description":"<h4>Background</h4>The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic stage in HER2-positive breast cancer patients enrolled in the ShortHER trial.<h4>Methods</h4>The ShortHER trial randomized 1253 HER2-positive patients to 9 weeks or 1 year of adjuvant trastuzumab combined with chemotherapy. Patients were classified according to the anatomic and the prognostic stage. Distant disease-free survival (DDFS) was calculated from randomization to distant relapse or death.<h4>Results</h4>A total of 1244 patients were included. Compared to anatomic stage, the prognostic stage downstaged 41.6% (n = 517) of patients to a more favorable stage category. Five","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Nov","modification":"2026-04-14T11:21:55.801Z","creation":"2025-06-01T03:50:48.011Z"},"accession":"S-EPMC6868696","cross_references":{"pubmed":["31747948"],"doi":["10.1186/s12916-019-1445-z"]}}